

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number
WO 01/47493 A1

- (51) International Patent Classification⁷: **A61K 9/12**
- (21) International Application Number: **PCT/GB00/04939**
- (22) International Filing Date:
21 December 2000 (21.12.2000)
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
9930878.5 24 December 1999 (24.12.1999) GB
0018686.6 28 July 2000 (28.07.2000) GB
- (71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED [GB/GB]**; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (71) Applicants and
(72) Inventors: **CRIPPS, Alan, Leslie [GB/GB]**; Glaxo Wellcome plc, Park Road, Ware, Hertfordshire SG12 0DP (GB).
JOHNSON, Paul [GB/GB]; Glaxo Wellcome plc, Park Road, Ware, Hertfordshire SG12 0DP (GB).
- (74) Agent: **TEUTEN, Andrew**; Glaxo Wellcome Plc, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PHARMACEUTICAL AEROSOL FORMULATION OF SALMETEROL AND FLUTICASONE PROPIONATE**

(57) Abstract: There is provided according to the invention a pharmaceutical aerosol formulation which comprises: (i) salmeterol or a pharmaceutically acceptable salt thereof, (ii) fluticasone propionate and (iii) a hydrofluoroalkane (HFA) propellant, characterised in that the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate are completely dissolved in the formulation.

WO 01/47493 A1

PHARMACEUTICAL AEROSOL FORMULATION OF SALMETEROL AND FLUTICASONE PROPIONATE

Background of the InventionField of the Invention

The present invention relates to pharmaceutical formulations for use in the administration of medicaments by inhalation. In particular, this invention relates to pharmaceutical formulations of fluticasone propionate and salmeterol or a pharmaceutically acceptable salt thereof (such as the xinafoate) for use in pressurised metered dose inhalers (MDI's). The invention also relates to methods for their preparation and to their use in therapy.

Description of the Background Art

Inhalers are well known devices for administering pharmaceutically active materials to the respiratory tract by inhalation. Such active materials commonly delivered by inhalation include bronchodilators such as β_2 agonists and anticholinergics, corticosteroids, anti-allergics and other materials that may be efficiently administered by inhalation, thus increasing the therapeutic index and reducing side effects of the active material.

4-hydroxy- α^1 -[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-1,3-benzenedimethanol was described as one of a wide range of bronchodilators in GB-A-2140800. This compound is also known by the generic name of salmeterol, the xinafoate salt of which has become widely known as a highly effective treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

(6a, 11b, 16a, 17a)-6, 9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy) androsta-1, 4-diene-17-carbothioic acid, S-fluoromethyl ester was described as an anti-inflammatory steroid by US Patent No. 4,335,121. This compound is also known by the generic name of fluticasone propionate and has since become widely known as a highly effective steroid in the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Coadministration of salmeterol and fluticasone propionate is believed to have significant advantages in the treatment and control of these inflammatory diseases.

Metered dose inhalers (MDI's) are the most common type of a wide range of inhaler types and utilise a liquefied propellant to expel droplets containing the pharmaceutical product to the respiratory tract as an aerosol. MDI formulations are generally characterised as solution formulations or suspension formulations.

The most commonly used aerosol propellants for medicaments have been Freon 11 (CCl_3F) in admixture with Freon 12 (CCl_2F_2) and Freon 114 ($\text{CF}_2\text{Cl.CF}_2\text{Cl}$). However, these propellants are now believed to provoke the degradation of stratospheric ozone and their use is now being phased out to eliminate the use of all CFC containing aerosol propellants. There is thus a need to provide an aerosol formulation for medicaments which employ so called 'ozone-friendly' propellants.

Hydrofluoroalkanes (HFAs; known also as hydrofluorocarbons or HFCs) contain no chlorine and are considered less destructive to ozone and these are proposed substitutes for CFCs. In particular, 1,1,1,2-tetrafluoroethane (HFA 134a) and 1,1,1,2,3,3,3-heptafluoropropane (HFA 227) have been acknowledged to be the best candidates for non-CFC propellants.

The efficiency of an aerosol device, such as an MDI, is a function of the dose deposited at the appropriate site in the lungs. Deposition is affected by several factors, of which one of the most important is the aerodynamic particle size. Solid particles and/or droplets in an aerosol formulation can be characterised by their mass median aerodynamic diameter (MMAD, the diameter around which the mass aerodynamic diameters are distributed equally).

Particle deposition in the lung depends largely upon three physical mechanisms:

1. impaction, a function of particle inertia;
2. sedimentation due to gravity; and
3. diffusion resulting from Brownian motion of fine, submicrometer ($<1\mu\text{m}$) particles.

The mass of the particles determines which of the three main mechanisms predominates.

The effective aerodynamic diameter is a function of the size, shape and density of the particles and will affect the magnitude of forces acting on them. For example, while inertial and gravitational effects increase with increasing particle size and particle density, the displacements produced by diffusion decrease. In practice, diffusion plays little part in deposition from pharmaceutical aerosols. Impaction and sedimentation can be assessed from a measurement of the MMAD which determines the displacement across streamlines under the influence of inertia and gravity, respectively.

Aerosol particles of equivalent MMAD and GSD (geometric standard deviation) have similar deposition in the lung irrespective of their composition. The GSD is a measure of the variability of the aerodynamic particle diameters.

For inhalation therapy there is a preference for aerosols in which the particles for inhalation have a diameter of about 0.5 to 5 μ m. Particles which are larger than 5 μ m in diameter are primarily deposited by inertial impaction in the oropharynx, particles 0.5 to 5 μ m in diameter, influenced mainly by gravity, are ideal for deposition in the conducting
5 airways, and particles 0.5 to 3 μ m in diameter are desirable for aerosol delivery to the lung periphery. Particles smaller than 0.5 μ m may be exhaled.

Respirable particles are generally considered to be those with aerodynamic diameters less than 5 μ m. These particles, particularly those with a diameter of about 3 μ m, are efficiently deposited in the lower respiratory tract by sedimentation.

10 It has been recently demonstrated in patients with mild and severe airflow obstruction that the particle size of choice for a β 2 agonist or anticholinergic aerosol should be approximately 3 μ m (Zaanen, P. et al, Int. J. Pharm. (1994) 107, 211-217, Int. J. Pharm. (1995) 114, 111-115, Thorax (1996), 51, 977-980.)

Many of the factors relevant to the MMAD of particles are relevant to droplets and the
15 additional factors of rate of solvent evaporation, and surface tension are also important.

In suspension formulations, particle size in principle is controlled during manufacture by the size to which the solid medicament is reduced, usually by micronisation. However, if the suspended drug has the slightest solubility in propellant, a process known as Ostwald Ripening can lead to particle size growth. Also, particles may have
20 tendency to aggregate, or adhere to parts of the MDI eg. canister or valve. The effect of Ostwald ripening and particularly of drug deposition may be particularly severe for potent drugs (including salmeterol xinafoate and fluticasone propionate) which need to be formulated in low doses. Solution formulations do not suffer from these disadvantages, but suffer from different ones in that particle or droplet size is both a
25 function of rate of evaporation of the propellant from the formulation, and of the time between release of formulation from the canister and the moment of inhalation. Thus, it may be subject to considerable variability and is generally hard to control.

Besides its impact on the therapeutic profile of a drug, the size of aerosol particles has an important impact on the side effect profile of a drug. For example, it is well
30 known that the oropharynx deposition of aerosol formulations of steroids can result in side effects such as candidiasis of mouth and throat. Furthermore, a higher systemic exposure to the aerosol particles due to deep lung penetration can enhance the

undesired systemic effects of certain drugs. For example, the systemic exposure to certain steroids can produce side effects on bone metabolism and growth.

We have now invented a formulation of salmeterol or a pharmaceutically acceptable salt thereof and fluticasone propionate which eliminates or substantially mitigates some or all of the abovementioned disadvantages.

Summary of the Invention

Thus, according to the present invention we provide a pharmaceutical aerosol formulation, comprising (i) salmeterol or a pharmaceutically acceptable salt thereof, (ii) fluticasone propionate and (iii) a hydrofluoroalkane (HFA) propellant; and characterised in that the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate are completely dissolved in the formulation.

Detailed description of the Invention

The formulation will generally contain a solubilisation agent to aid solubilisation of the salmeterol or pharmaceutically acceptable salt thereof and the fluticasone propionate in the formulation. Suitable solubilisation agents include propylene glycol and ethanol, preferably ethanol. Other suitable solubilisation agents include ethers eg dimethyl ether. Alkanes may also be of use. A further solubilisation agent of possible interest is dimethoxymethane which has good solvency properties. Ethylacetate may also be of interest.

As a particular aspect of the present invention we provide a pharmaceutical aerosol formulation, comprising (i) salmeterol or a pharmaceutically acceptable salt thereof, (ii) fluticasone propionate, (iii) a hydrofluoroalkane (HFA) propellant, (iv) a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler and (v) a solubilisation agent in sufficient quantity to solubilise the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate in the formulation.

The presence of the low volatility component in the solution formulation increases the fine particle mass (FPM) as defined by the content of stages 3-5 of an Andersen Cascade Impactor on actuation of the formulation relative to solutions formulations which omit this component. Solution formulations which omit the higher volatility component generally give rise to a particle size distribution which have a higher content of finer particles; such distributions generally do not match the distribution of suspension formulations and may therefore not be bio-equivalent.

Examples of HFA propellants include 1,1,1,2-tetrafluoroethane (HFA134a) and 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227) and mixtures thereof. The preferred propellant is 1,1,1,2-tetrafluoroethane (HFA134a). An alternative preferred propellant is 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227).

5 The preferred low volatility component is glycerol, propylene glycol or polyethyleneglycol. Glycerol is of particular interest. Polyethylene glycol (eg PEG200 or PEG400) is also of particular interest. Preferably the low volatility component is present in an amount of 0.5 to 3% (w/w)

The preferred solubilisation agent is ethanol.

10 In a first embodiment of the invention we prefer salmeterol to be used in the form of the xinafoate salt. Salmeterol xinafoate may be prepared in two polymorphic forms known as Form I and Form II. Form I which has a melting endotherm at 140 °C may be prepared by precipitation from a hot methanolic solution of salmeterol xinafoate on addition to cold isopropanol as described in International Patent Application No.
15 WO93/16031. Form II which has a melting endotherm at 125 °C may be prepared by supercritical fluid recrystallisation as described in International Patent Application No. WO95/01324. Preferably salmeterol xinafoate is employed as Form II polymorph since this form would be predicted to have a higher solubility. Alternatively salmeterol xinafoate may be employed as the Form I polymorph.

20 More particularly we prefer to use salmeterol xinafoate in the form of the purified enantiomer R-salmeterol xinafoate. Surprisingly we have found that R-salmeterol xinafoate in a polymorphic form obtainable by crystallisation from ether is significantly more soluble in mixtures of ethanol/HFA134a and ethanol/HFA227 than racemic salmeterol xinafoate. Without being limited by theory, this higher solubility may be
25 attributed to the low crystal lattice energy as demonstrated by a melting endotherm at 95 °C (which is considerably lower than that of the two forms of salmeterol xinafoate mentioned above).

In a second embodiment of the invention we prefer to use salmeterol as the free base.

30 Surprisingly we have found that salmeterol base is substantially more soluble in mixtures of ethanol/HFA134a and ethanol/HFA227 than racemic salmeterol xinafoate or even R-salmeterol xinafoate. It is also of interest to use salmeterol base as R-salmeterol base.

Use of R-salmeterol xinafoate or base has the further advantage that it takes advantage of the higher potency of R-salmeterol relative to racemic salmeterol with the result that a lower concentration of the drug in solution is required.

5 In a third less preferred embodiment salmeterol is used as the sulphate salt. The preferred solubilising agent for salmeterol sulphate is propylene glycol.

As is apparent from the examples, formulations of salmeterol base and fluticasone propionate in ethanol and HFA134a or HFA227, particularly together with the a low volatility component such as glycerol or polyethyleneglycol, show particularly excellent delivery characteristics.

10 In the foregoing, except where otherwise indicated, drug quantities of salmeterol are given as appropriate for salmeterol base but it will be understood that for a salmeterol xinafoate or another pharmaceutically acceptable salt thereof an appropriate conversion to give a suitable weight of active principal in the delivered dose may be made. For example a dose of 25 µg of salmeterol equates to a dose of 36.3 µg of salmeterol
15 xinafoate. It will also be understood that salmeterol may be used as the racemate (as is preferred) or in the form of an enantiomerically enriched (or purified) single R- or S-enantiomer. In the foregoing drug quantities are given as appropriate for racemic drug but it will be understood that adjustment of the dosage weight may be appropriate when a different ratio of enantiomers is employed. For example R-salmeterol may desirably
20 be employed at one half of the normal dose of racemic salmeterol.

We prefer the formulation to be suitable for delivering a therapeutic amount of salmeterol and fluticasone propionate in one or two actuations. Preferably the formulation will be suitable for delivering 25-50 µg salmeterol per actuation, especially 25 µg per actuation of salmeterol (eg as xinafoate). Preferably, the formulation will be
25 suitable for delivering 25-250µg fluticasone propionate per actuation, particularly 25µg, 50µg, 125µg or 250µg especially 25µg or 50µg per actuation of fluticasone propionate.

The formulation according to the invention will be used in association with a suitable metering valve. We prefer that the formulation is actuated by a metering valve capable of delivering a volume of between 50µl and 100µl eg 50µl or 63µl or, more preferably,
30 100µl.

For a 25 µg dose, when a 50µl metering volume is used, the final concentration of salmeterol delivered per actuation would be 0.05% (w/v) or 0.042% (w/w). Wherein a 63µl metering volume is used, the final concentration of salmeterol delivered per

actuation would be 0.04% (w/v) or 0.033% (w/w). If a 100 µl metering valve were to be used, for a 25 µg dose the final concentration of salmeterol to delivered per actuation would be 0.025% (w/v) or 0.021% (w/w).

When a 50µl metering volume is used, the final concentration of fluticasone propionate delivered per actuation would be 0.1% w/v (which equates to 0.1g of fluticasone propionate per 100ml of formulation) or approx. 0.083% w/w (which equates to 0.083g of fluticasone propionate per 100g of formulation) for a 50µg dose, 0.25% (w/v) or approx. 0.21% (w/w) for a 125µg dose, 0.5% (w/v) or approx. 0.42% (w/w) for a 250µg dose and 0.05% (w/v) or approx 0.042% (w/w) for a 25µg dose. When a 63µl metering volume is used, the final concentration of fluticasone propionate delivered per actuation would be 0.079% (w/v) or approx. 0.067% (w/w) for a 50µg dose, 0.198% (w/v) or approx. 0.167% (w/w) for a 125µg dose, 0.397% (w/v) or approx. 0.333% (w/w) for a 250µg dose and 0.04% (w/v) or approx. 0.033% (w/w) for a 25µg dose. When a 100µl metering volume is used, the final concentration of fluticasone propionate delivered per actuation would be 0.05% w/v or approx. 0.042% w/w for a 50µg dose, 0.13% (w/v) or approx. 0.10% (w/w) for a 125µg dose, 0.25% (w/v) or approx. 0.21% (w/w) for a 250µg dose and 0.025% (w/v) or approx 0.021% (w/w) for a 25µg dose.

The previously referred to w/w figures are approximate in that they do not compensate for the density mismatch between HFA134a and ethanol, however the precise figures may be readily determined.

Use of a larger metering chamber volume eg 100µl is generally preferred.

We prefer the formulation to contain between 0.5 and 2% (w/w) of the low volatility component, more preferably between 0.8 and 1.6% (w/w), particularly between 1.0 and 1.6% (w/w). We especially prefer to use 1.3% (w/w). We also especially prefer to use 1.0% (w/w) of the low volatility component. However the most preferred range is 0.5-1% (w/w) eg 0.5%, 0.75% or 1% (w/w).

It is necessary to employ the low volatility component, the solubilising agent and the propellant in relative proportions such that the components are freely miscible.

Depending on the final concentration of salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate in the formulation, the propellant, and the precise amount of low volatility component, the concentration of solubilisation agent (eg ethanol) required will vary. So as not to suppress the vapour pressure of the propellant to an undesirable extent, the amount of ethanol should preferably not exceed around

35%. The amount of ethanol will more preferably be in the range 5 to 30%, more particularly 5-15% especially 6-12% eg 7-10% w/w.

When the concentration of salmeterol xinafoate is around 0.025% w/v, the concentration of fluticasone propionate is around 0.05% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 21-24% w/w, especially around 22% w/w is particularly suitable. When the concentration of salmeterol xinafoate is around 0.025% w/v, the concentration of fluticasone propionate is around 0.025% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 17-20% w/w, especially around 18% w/w is particularly suitable.

When the concentration of salmeterol (as xinafoate) is around 0.025% w/v, the concentration of fluticasone propionate is around 0.025% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 23-26% w/w, especially around 25% w/w is particularly suitable. When the concentration of salmeterol (as xinafoate) is around 0.025% w/v, the concentration of fluticasone propionate is around 0.05% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 21-24% w/w, especially around 23% w/w is particularly suitable. When the concentration of salmeterol (as xinafoate) is around 0.025% w/v, the concentration of fluticasone propionate is around 0.13% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 20-23% w/w, especially around 21% w/w is particularly suitable.

When the concentration of salmeterol (as xinafoate) is around 0.025% w/v, the concentration of fluticasone propionate is around 0.25% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 39-42% w/w, especially around 41% w/w is particularly suitable.

The concentration of salmeterol expressed as weight of xinafoate will preferably be in the range 0.02-0.05% w/v especially 0.02-0.03% w/v eg around 0.025% w/v (equivalent to 0.014%-0.035% w/v especially 0.014%-0.021% w/v eg around 0.017% w/v expressed as weight of base). Another range of interest is 0.017-0.028% w/v eg around 0.025% w/v expressed as weight of base. The concentration of fluticasone propionate will preferably be in the range 0.02-0.2% w/v especially 0.02-0.15% w/v eg 0.025-0.13% w/v, especially 0.025-0.05% w/v.

For a salmeterol concentration of 0.025% w/v (as xinafoate) we have surprisingly found that the amount of ethanol required to solubilise salmeterol xinafoate and fluticasone propionate in a formulation in HFA134a declines as the fluticasone propionate concentration increases from 0.025% w/v to 0.13% w/v. This implies that

there may be some interaction between the salmeterol (as xinafoate) and fluticasone propionate in the formulation. In light of this observation we have appreciated that the formulations employing a higher strength of fluticasone propionate may be formulated with a lower amount of ethanol than might otherwise be expected. This results in a number of advantages, for example that such formulations have a higher than anticipated fine particle mass (FPM).

Thus we prefer the ratio of the concentration of salmeterol (particularly as xinafoate) to fluticasone propionate expressed in w/v terms with weight of salmeterol being expressed as weight of free base to be in the range 1:1 to 1:6 particularly 1:2 to 1:6 eg around 1:5. In concentration terms these ratios are preferably employed when the number "1" corresponds to a concentration of around 0.025% w/v.

The above ethanol concentrations are appropriate for salmeterol xinafoate in the form of Form I polymorph. A somewhat lower concentration would be expected to be necessary for the Form II polymorph.

When the concentration of R-salmeterol (present as xinafoate) is 0.04 w/v (based on weight of R-salmeterol base), the concentration of fluticasone propionate is less than around 0.05% w/v (eg 0.025%, 0.04% or 0.05% w/v) and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 12-14% w/w eg 13% w/w is suitable. When the concentration of R-salmeterol (present as xinafoate) is 0.025 w/v (based on weight of R-salmeterol base), the concentration of fluticasone propionate is less than around 0.05% w/v (eg 0.025%, 0.04% or 0.05% w/v) and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of 9-11% w/w eg 10% w/w is suitable. When the concentration of R-salmeterol (present as xinafoate) is 0.025 w/v (based on weight of R-salmeterol base), the concentration of fluticasone propionate is around 0.025% w/v and the propellant is 1,1,1,2,3,3,3-heptafluoro-n-propane, an amount of ethanol of 13-15% w/w eg 14% w/w is suitable.

When the concentration of salmeterol (present as free base) is 0.05 w/v, the concentration of fluticasone propionate is around 0.05% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of around 9-11% w/w eg 10% w/w is suitable. When the concentration of salmeterol (present as free base) is 0.04 w/v, the concentration of fluticasone propionate is around 0.04% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of around 8-10% w/w eg 9% w/w is suitable. When the concentration of salmeterol (present as free base) is 0.025 w/v, the concentration of fluticasone propionate is around 0.05% w/v and the propellant is

1,1,1,2-tetrafluoroethane, an amount of ethanol of around 9-11% w/w eg 10% w/w is suitable. When the concentration of salmeterol (present as free base) is 0.025 w/v, the concentration of fluticasone propionate is around 0.025% w/v and the propellant is 1,1,1,2-tetrafluoroethane, an amount of ethanol of around 6-10% preferably 6-8% w/w eg 7% w/w is suitable.

When the concentration of salmeterol (present as free base) is around 0.025% w/v, the concentration of fluticasone propionate is around 0.025% w/v and the propellant is 1,1,1,2,3,3,3-heptafluoro-n-propane, an amount of ethanol of 13-15% preferably around 14% w/w is suitable.

The preferred concentration of salmeterol (as free base) in the formulation is 0.025-0.05% w/v. The preferred concentration of fluticasone propionate in the formulation is 0.025-0.13% w/v more preferably 0.025-0.05% w/v, particularly around 0.025% w/v. When 1,1,1,2-tetrafluoroethane is the propellant the preferred concentration of ethanol as solubilising agent in the formulation is around 6-12% eg 7-10% w/w. When 1,1,1,2,3,3,3-heptafluoro-n-propane is the propellant the preferred concentration of ethanol as solubilising agent in the formulation 13-15% eg around 14% w/w.

Formulations according to the invention which are free of surfactants are preferred. Formulations according to the invention which are free of all excipients besides the solubilisation agent (eg ethanol), low volatility component (such as glycerol or polyethyleneglycol) and the propellant are particularly preferred.

We have also surprisingly found that whereas fluticasone propionate seems quite stable to chemical degradation on storage in an ethanol/HFA134a solution, salmeterol (eg as free base or xinafoate) shows a tendency to exhibit chemical degradation. Without being limited by theory we believe that this chemical degradation may be due to acid catalysed dimerisation of the salmeterol. Thus it may be preferred to incorporate an agent in an amount capable of suppressing chemical degradation of salmeterol in the formulation. For examples agents capable of preventing acid catalysed dimerisation include bases such as sodium or potassium hydroxide or sodium carbonate or an organic amine. It may be necessary also to incorporate a small quantity of water into the formulation eg 0.05-2% w/w water or more preferably 0.1-1% w/w water. Chemical degradation may also be promoted by oxidation eg arising from trace amounts of peroxide present in valve components (such as peroxide cured rubbers) or excipients. Preferably peroxide contamination will be avoided eg by use of appropriately cleansed valve components and the like. Alternatively an anti-oxidant may be employed

(preferably one which is not an acid). Formulations according to the invention which are free of all excipients besides the solubilisation agent (eg ethanol), low volatility component (such as glycerol or polyethylene glycol, the agent capable of suppressing chemical degradation of salmeterol and any water in the formulation and the propellant are also preferred.

The pharmaceutical composition according to the present invention may be filled into canisters suitable for delivering pharmaceutical aerosol formulations. Canisters generally comprise a container capable of withstanding the vapour pressure of the HFA propellant, such as plastic or plastic-coated glass bottle or preferably a metal can, for example an aluminium can which may optionally be anodised, lacquer-coated and/or plastic-coated, which container is closed with a metering valve. Canisters may be coated with a polymer as described in WO 96/32151, for example, a co-polymer of polyethersulphone (PES) and polytetrafluoroethylene (PTFE). Another polymer for coating that may be contemplated is FEP (fluorinated ethylene propylene). The metering valves are designed to deliver a metered amount of the formulation per actuation and incorporate a gasket to prevent leakage of propellant through the valve. The gasket may comprise any suitable elastomeric material such as for example low density polyethylene, chlorobutyl, black and white butadiene-acrylonitrile rubbers, butyl rubber, neoprene, EPDM (eg as described in WO95/02651) and TPE (thermoplastic elastomer; eg as described in WO92/11190). EPDM and TPE rubbers are preferred. Suitable valves are commercially available from manufacturers well known in the aerosol industry, for example, from Valois, France (eg. DF10, DF30, DF60), Bepak plc, UK (eg. BK300, BK356, BK357) and 3M-Neotechnic Ltd, UK (eg. Spraymiser™). The DF31 valve of Valois, France is also suitable.

Valve seals, especially the gasket seal, and also the seals around the metering chamber, will preferably be manufactured of a material which is inert to and resists extraction into the contents of the formulation, especially when the contents include ethanol.

Valve materials, especially the material of manufacture of the metering chamber, will preferably be manufactured of a material which is inert to and resists distortion by contents of the formulation, especially when the contents include ethanol. Particularly suitable materials for use in manufacture of the metering chamber include polyesters eg polybutyleneterephthalate (PBT) and acetals, especially PBT.

Materials of manufacture of the metering chamber and/or the valve stem may desirably be fluorinated, partially fluorinated or impregnated with fluorine containing substances in order to resist drug deposition.

5 Valves which are entirely or substantially composed of metal components (eg Spraymiser, 3M-Neotechnic) are especially preferred for use according to the invention.

10 Conventional bulk manufacturing methods and machinery well known to those skilled in the art of pharmaceutical aerosol manufacture may be employed for the preparation of large scale batches for the commercial production of filled canisters. Thus, for example, in one bulk manufacturing method a metering valve is crimped onto an aluminium can to form an empty canister. The medicament is added to a charge vessel and a mixture of ethanol, low volatility component and liquefied propellant is pressure filled through the charge vessel into a manufacturing vessel. An aliquot of the formulation is then filled through the metering valve into the canister.

15 In an alternative process, an aliquot of the liquified formulation is added to an open canister under conditions which are sufficiently cold that the formulation does not vaporise, and then a metering valve crimped onto the canister.

In an alternative process an aliquot of medicament dissolved in the solubilising agent and any low-volatility component is dispensed into an empty canister, a metering valve is crimped on, and then the propellant is filled into the canister through the valve.

20 Typically, in batches prepared for pharmaceutical use, each filled canister is check-weighed, coded with a batch number and packed into a tray for storage before release testing.

25 Each filled canister is conveniently fitted into a suitable channelling device prior to use to form a metered dose inhaler for administration of the medicament into the lungs or nasal cavity of a patient. Suitable channelling devices comprise, for example a valve actuator and a cylindrical or cone-like passage through which medicament may be delivered from the filled canister via the metering valve to the nose or mouth of a patient eg. a mouthpiece actuator.

30 In a typical arrangement the valve stem is seated in a nozzle block which has an orifice leading to an expansion chamber. The expansion chamber has an exit orifice which extends into the mouthpiece. Actuator (exit) orifice diameters in the range 0.15-0.45mm particularly 0.2-0.45mm are generally suitable eg 0.25, 0.30, 0.33 or 0.42mm. We have found that it is advantageous to use a small diameter eg 0.25mm or less, particularly 0.22mm since this tends to result in a higher FPM and lower throat

deposition. 0.15mm is also particularly suitable. The dimensions of the orifice should not be so small that blockage of the jet occurs.

Actuator jet lengths are typically in the range 0.30-1.7mm eg 0.30, 0.65 or 1.50mm. Smaller dimensions are preferred eg 0.65mm or 0.30mm.

5 For the avoidance of water ingress into the formulation it may be desired to overwrap the MDI product in a flexible package capable of resisting water ingress and capable of permitting absorption or release of any propellant which may leak from the canister. It may also be desired to incorporate a desiccant within the packaging. Example overwraps are described in US Patent 6119853.

10 Metered dose inhalers are designed to deliver a fixed unit dosage of medicament per actuation or 'puff', for example in the range of 10 to 5000 µg medicament per puff.

Administration of medicament may be indicated for the treatment of mild, moderate or severe acute or chronic symptoms or for prophylactic treatment. Treatment may be of asthma, chronic obstructive pulmonary disease (COPD) or other respiratory disorder.
15 It will be appreciated that the precise dose administered will depend upon the age and condition of the patient, the quantity and frequency of administration will ultimately be at the discretion of the attendant physician. Typically, administration may be one or more times, for example from 1 to 8 times per day, giving for example 1,2,3 or 4 puffs each time.

20 The preferred treatment regime is 2 puffs of 25µg/puff salmeterol (eg as xinafoate) and 25, 50, 125 or 250µg/puff (particularly 25 or 50µg/puff) fluticasone propionate, 2 times per day.

The filled canisters and metered dose inhalers described herein comprise further aspects of the present invention.

25 A still further aspect of the present invention comprises a method of treating respiratory disorders such as, for example, asthma or chronic obstructive pulmonary disease (COPD), which comprises administration by inhalation of an effective amount of a formulation herein before described.

A further aspect of the present invention comprises the use of a formulation herein
30 before described in the manufacture of a medicament for the treatment of respiratory disorders, eg. asthma or chronic obstructive pulmonary disease (COPD).

As mentioned above the advantages of the invention in some or all of its embodiments include the fact that formulations according to the invention may be more

environmentally friendly, more stable, less susceptible to Ostwald ripening or drug deposition onto internal surfaces of a metered dose inhaler, have better dosing uniformity, deliver a higher FPM, give lower throat deposition, be more easily or economically manufactured, or may be otherwise beneficial relative to known formulations.

The invention is illustrated with reference to the following examples:

Examples 1 and 2

Formulations may be prepared with composition as follows:

Salmeterol xinafoate:	0.025% w/v
Fluticasone propionate:	0.05% w/v
Ethanol:	22% w/w
Glycerol:	1.3% w/w
1,1,1,2-tetrafluoroethane:	to 100%

This solution formulation may be filled into an aluminium canister under pressure and fitted with a metering valve having a 100 µl metering chamber.

Salmeterol xinafoate:	0.025% w/v
Fluticasone propionate:	0.025% w/v
Ethanol:	18% w/w
Glycerol:	1.3% w/w
1,1,1,2-tetrafluoroethane:	to 100%

This solution formulation may be filled into an aluminium canister under pressure and fitted with a metering valve having a 100 µl metering chamber.

Example 3

A formulation was prepared with compositions as follows:

Salmeterol (as xinafoate):	0.025% w/v (based on weight of salmeterol base)
Fluticasone propionate:	0.025% w/v
Ethanol:	25% w/w
Glycerol:	1.0% w/w
1,1,1,2-tetrafluoroethane:	to 100%

This solution formulation was filled into an aluminium canister (120 actuations/canister; overage of 40 actuations) under pressure and fitted with a metering

valve (Valois DF60) having metering chamber of volume 100 μ l. This formulation is suitable for delivering 25 μ g salmeterol and 25 μ g fluticasone propionate per actuation.

Example 4

5 A formulation was prepared with compositions as follows:

Salmeterol (as xinafoate): 0.025% w/v (based on weight of salmeterol base)

Fluticasone propionate: 0.05% w/v

Ethanol: 23% w/w

Glycerol: 1.0% w/w

10 1,1,1,2-tetrafluoroethane: to 100%

This solution formulation was filled into an aluminium canister (120 actuations/canister; overage of 40 actuations) under pressure and fitted with a metering valve (Valois DF60) having metering chamber of volume 100 μ l. This formulation is suitable for delivering 25 μ g salmeterol and 50 μ g fluticasone propionate per actuation.

15

Example 5

A formulation was prepared with compositions as follows:

Salmeterol (as xinafoate): 0.025% w/v (based on weight of salmeterol base)

Fluticasone propionate: 0.13% w/v

20 Ethanol: 21% w/w

Glycerol: 1.0% w/w

1,1,1,2-tetrafluoroethane: to 100%

This solution formulation was filled into an aluminium canister (120 actuations/canister; overage of 40 actuations) under pressure and fitted with a metering valve (Valois DF60) having metering chamber of volume 100 μ l. This formulation is suitable for delivering 25 μ g salmeterol and 125 μ g fluticasone propionate per actuation.

25

Examples 6-8

Formulations were prepared with composition as follows:

30 Salmeterol (as free base): 0.025% w/v

Fluticasone propionate: 0.025% w/v

Ethanol: 7% w/w

Glycerol or PEG200 or PEG400: 0.5% w/w

1,1,1,2-tetrafluoroethane: to 100%

These solution formulations were filled into an aluminium canister (120 actuations/canister; overage of 40 actuations) under pressure and fitted with a metering valve (Valois DF60) having metering chamber of volume 100 μ l. These formulations are suitable for delivering 25 μ g salmeterol and 25 μ g fluticasone propionate per actuation.

Examples 9-11

Formulations were prepared with composition as follows:

Salmeterol (as free base): 0.025% w/v
Fluticasone propionate: 0.05% w/v
Ethanol: 10% w/w
Glycerol or PEG200 or PEG400: 0.5% w/w
1,1,1,2-tetrafluoroethane: to 100%

These solution formulations were filled into an aluminium canister (120 actuations/canister; overage of 40 actuations) under pressure and fitted with a metering valve (Valois DF60) having metering chamber of volume 100 μ l. These formulations are suitable for delivering 25 μ g salmeterol and 50 μ g fluticasone propionate per actuation.

Example 12-20

The formulations of Examples 3-11 may also be prepared omitting the glycerol or polyethyleneglycol.

Andersen Cascade Impaction Data

Formulations as described in Examples 6 to 11 were profiled using an Andersen Cascade Impactor, using a 0.22mm (orifice) x 0.65mm (jet length) actuator from Bepak (BK621 variant). Testing was performed on canisters at "beginning of use" (BoU) and delivered drug from 10 actuations was collected in the instrument after 4 priming actuations were fired to waste. Results are shown in Tables 1 to 4 and Figures 1 and 2. Product on the individual stages of the Cascade Impactor was dissolved up in aqueous methanol and eluted through an HPLC column (stationary phase: 20cm C₁₈ reverse phase (Hypersil); mobile phase: methanol/MeCN buffered with ammonium acetate) in order to allow the respective amounts of salmeterol and fluticasone propionate to be determined (these amounts being shown separately in the Tables and Figures below).

Brief Description of the Tables:

Table 1: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 7% ethanol with 0.5% of various low volatility components (as per Examples 6-8) (microgram data)

Table 2: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 7% ethanol with 0.5% of various low volatility components (as per Examples 6-8) (percentage data)

Table 3: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 10% ethanol with 0.5% of various low volatility components (as per Examples 9-11) (microgram data)

Table 4: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 10% ethanol with 0.5% of various low volatility components (as per Examples 9-11) (percentage data)

Brief Description of the Figures:

Figure 1: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 7% ethanol with 0.5% of various low volatility components (microgram data) (Data as per Table 1)

Figure 2: Cascade Impaction analysis of salmeterol and fluticasone propionate/HFA134a solution aerosols containing 10% ethanol with 0.5% of various low volatility components (microgram data) (Data as per Table 3)

From the Tables and Figures it may be deduced that exceptionally good data in terms of fine particle mass is obtained from the use of salmeterol base and fluticasone propionate using ethanol as solubilising agent and HFA134a as propellant with glycerol or polyethylene glycol (PEG200, PEG400) as low volatility component. Furthermore these data on salmeterol and fluticasone propionate in solution formulation together are very similar to data on salmeterol and fluticasone propionate in solution formulation individually. They are also similar to corresponding data on the currently marketed excipient free suspension formulation of salmeterol xinafoate and fluticasone propionate in HFA134a (Seretide Evohaler).

Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps. Above
5 mentioned patents and patent applications are hereinbefore incorporated by reference.

Fluticasone propionate µg Results Cascade Impaction

Table 1

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	7% w/w EtOH + 0.5% w/w PEG	7% w/w EtOH + 0.5% w/w
Device	2.9	2.7	3.1
Throat	5.9	5.8	5.6
Stage 0	0.5	0.7	0.8
Stage 1	0.2	0.2	0.2
Stage 2	0.4	0.4	0.4
Stage 3	1.7	1.8	1.8
Stage 4	4.3	4.2	4.3
Stage 5	7.4	6.9	7.1
Stage 6	2.1	2.3	2.3
Stage 7	1.0	1.0	1.2
Filter	0.6	0.4	0.4
Total	26.8	26.3	26.9
Total Ex-Device	23.9	23.6	23.8
FPM Sum S13, S14, S15	13.4	12.9	13.1
MMAD	1.7	1.8	1.8
GSD	1.9	2.0	2.0

Salmeterol base µg Results Cascade Impaction

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	7% w/w EtOH + 0.5% w/w PEG 200	7% w/w EtOH + 0.5% w/w
Device	2.6	2.8	3.0
Throat	5.3	5.7	5.3
Stage 0	0.5	0.7	0.6
Stage 1	0.1	0.2	0.1
Stage 2	0.3	0.3	0.3
Stage 3	1.5	1.8	1.7
Stage 4	3.9	4.2	4.2
Stage 5	6.5	6.9	7.0
Stage 6	1.9	2.3	2.3
Stage 7	0.9	1.0	1.1
Filter	0.4	0.3	0.3
Total	23.5	25.9	25.7
Total Ex-Device	21.0	23.1	22.8
FPM Sum S13, S14, S15	11.8	12.8	12.9
MMAD	1.8	1.8	1.8
GSD	1.9	2.0	1.9

Table 2

Fluticasone propionate % Results Cascade Impaction

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	EtOH + 0.5% w/w PEG 200	EtOH + 0.5% w/w PEG 400
Device	10.8	10.3	11.5
Throat	22.0	22.1	20.8
Stage 0	1.9	2.7	3.0
Stage 1	0.7	0.8	0.7
Stage 2	1.5	1.5	1.5
Stage 3	6.3	6.8	6.7
Stage 4	16.0	16.0	16.0
Stage 5	27.6	26.2	26.4
Stage 6	7.8	8.7	8.6
Stage 7	3.7	3.8	4.5
Filter	2.2	1.5	1.5
Total	100.0	100.0	100.0
Total Ex-Device	89.2	89.7	88.7
FPM Sum St3, St4, St5	50.0	49.0	50.2

Salmeterol base % Results Cascade Impaction

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	7% w/w EtOH + 0.5% w/w PEG 200	EtOH + 0.5% w/w PEG 400
Device	11.1	10.8	11.7
Throat	22.6	22.0	20.6
Stage 0	2.1	2.7	2.3
Stage 1	0.4	0.8	0.4
Stage 2	1.3	1.2	1.2
Stage 3	6.4	6.9	6.6
Stage 4	16.6	16.2	16.3
Stage 5	27.7	26.6	27.2
Stage 6	8.1	8.9	8.9
Stage 7	3.8	3.9	4.3
Filter	1.7	1.2	1.2
Total	100.0	100.0	100.0
Total Ex-Device	89.4	89.2	88.7
FPM Sum St3, St4, St5	50.2	49.4	50.2

Table 3

Fluticasone propionate µg Results Cascade Impaction

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	7% w/w EtOH + 0.5% w/w 0.5% w/w	7% w/w EtOH + 0.5% w/w 0.5% w/w
Device	2.9	2.7	3.1
Throat	5.9	5.8	5.6
Stage 0	0.5	0.7	0.8
Stage 1	0.2	0.2	0.2
Stage 2	0.4	0.4	0.4
Stage 3	1.7	1.8	1.8
Stage 4	4.3	4.2	4.3
Stage 5	7.4	6.9	7.1
Stage 6	2.1	2.3	2.3
Stage 7	1.0	1.0	1.2
Filter	0.6	0.4	0.4
Total	26.8	26.3	26.9
Total Ex-Device	23.9	23.6	23.8
FPM Sum St3, St4, St5	13.4	12.9	13.1
MMAD	1.7	1.8	1.8
GSD	1.9	2.0	2.0

Salmeterol base µg Results Cascade Impaction

Sample ID	7% w/w EtOH + 0.5% w/w Glycerol	7% w/w EtOH + 0.5% w/w PEG 200	7% w/w EtOH + 0.5% w/w 0.5% w/w
Device	2.6	2.8	3.0
Throat	5.3	5.7	5.3
Stage 0	0.5	0.7	0.6
Stage 1	0.1	0.2	0.1
Stage 2	0.3	0.3	0.3
Stage 3	1.5	1.8	1.7
Stage 4	3.9	4.2	4.2
Stage 5	6.5	6.9	7.0
Stage 6	1.9	2.3	2.3
Stage 7	0.9	1.0	1.1
Filter	0.4	0.3	0.3
Total	23.5	25.9	25.7
Total Ex-Device	21.0	23.1	22.8
FPM Sum St3, St4, St5	11.8	12.8	12.9
MMAD	1.8	1.8	1.8
GSD	1.9	2.0	1.9

Table 4

Fluticasone propionate % Results Cascade Impaction

Sample ID	10% w/w EtOH + 0.5% w/w Glycerol	10% w/w EtOH + 0.5% w/w PEG 200	10% w/w EtOH + 0.5% w/w PEG 400
Device	9.1	10.3	8.5
Throat	29.9	27.6	32.9
Stage 0	3.9	4.5	3.4
Stage 1	0.8	0.8	0.8
Stage 2	1.4	1.4	1.3
Stage 3	6.3	6.7	6.2
Stage 4	14.6	14.6	13.9
Stage 5	23.2	22.5	21.6
Stage 6	6.3	7.1	7.0
Stage 7	3.1	3.4	3.4
Filter	1.8	1.4	1.5
Total	100.0	100.0	100.0
Total Ex-Device	90.9	89.9	91.9
FPM Sum S13, S14, S15	44.1	43.8	42.2

Salmeterol base % Results Cascade Impaction

Sample ID	10% w/w EtOH + 0.5% w/w Glycerol	10% w/w EtOH + 0.5% w/w PEG 200	10% w/w EtOH + 0.5% w/w PEG 400
Device	8.7	9.9	8.5
Throat	29.8	28.1	33.3
Stage 0	3.7	4.5	3.5
Stage 1	0.8	0.8	0.8
Stage 2	1.2	1.2	1.2
Stage 3	6.6	6.6	6.2
Stage 4	14.9	14.9	14.3
Stage 5	24.0	22.3	21.7
Stage 6	6.2	7.4	7.0
Stage 7	3.3	3.3	3.5
Filter	1.7	1.2	1.2
Total	100.0	100.0	100.0
Total Ex-Device	91.3	90.1	91.9
FPM Sum S13, S14, S15	45.0	43.8	42.2

Claims

1. A pharmaceutical aerosol formulation which comprises:
- 5 (i) salmeterol or a pharmaceutically acceptable salt thereof
(ii) fluticasone propionate and
(ii) a hydrofluoroalkane (HFA) propellant,
characterised in that the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate are completely dissolved in the formulation.
- 10 2. A formulation according to claim 1 which comprises:
- (i) salmeterol or a pharmaceutically acceptable salt thereof;
(ii) fluticasone propionate
(ii) a hydrofluoroalkane (HFA) propellant;
15 (iii) a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler; and
(iv) a solubilisation agent in sufficient quantity to solubilise the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate in the formulation.
- 20 3. A formulation according to claim 1 or claim 2 wherein the hydrofluoroalkane (HFA) propellant is 1,1,1,2-tetrafluoroethane (HFA134a).
4. A formulation according to claim 1 or claim 2 wherein the hydrofluoroalkane (HFA) propellant is 1,1,1,2,3,3,3-heptafluoro-n-propane (HFA227).
5. A formulation according to any one of claims 1 to 4 containing a low volatility
25 component which is glycerol.
6. A formulation according to any one of claims 1 to 4 containing a low volatility component which is polyethylene glycol.
7. A formulation according to claim 6 wherein the low volatility component is PEG200 or PEG400.
- 30 8. A formulation according to any one of claims 1 to 7 containing ethanol as solubilising agent in sufficient quantity to solubilise the salmeterol or pharmaceutically acceptable salt thereof and fluticasone propionate in the formulation.

9. A formulation according to claim 8 wherein the concentration of ethanol is 5 to 30% w/v.
10. A formulation according to claim 8 wherein the concentration of ethanol is 6 to 12% w/v.
- 5 11. A formulation according to any one of claims 1 to 10 wherein salmeterol is present as salmeterol base.
12. A formulation according to any one of claims 1 to 9 wherein salmeterol is present as the xinafoate salt.
- 10 13. A formulation according to claim 12 wherein salmeterol xinafoate is present in the form of its Form II polymorph.
14. A formulation according to claims 1 to 13 wherein the concentration of salmeterol expressed as weight of xinafoate is 0.02-0.03% w/v.
15. A formulation according to claims 1 to 13 wherein the concentration of salmeterol expressed as weight of base is 0.014-0.021% w/v.
- 15 16. A formulation according to claims 1 to 13 wherein the concentration of salmeterol expressed as weight of base is 0.017-0.028% w/v.
17. A formulation according to claim 16 wherein the concentration of salmeterol expressed as weight of base is around 0.025% w/v.
18. A formulation according to claim 11 wherein the concentration of salmeterol base is 0.025-0.05% w/v.
- 20 19. A formulation according to any one of claims 1 to 18 wherein salmeterol is present as R-salmeterol.
20. A formulation according to claims 1 to 19 wherein the concentration of fluticasone propionate is in the range 0.02-0.2% w/v.
- 25 21. A formulation according to claim 20 wherein the concentration of fluticasone propionate is in the range 0.02-0.15% w/v.
22. A formulation according to any one of claims 1 to 21 wherein the ratio of the concentration of salmeterol to fluticasone propionate expressed as w/v with weight of salmeterol being expressed as weight of free base is in the range
- 30 1:1 to 1:6.
23. A formulation according to claim 22 wherein in concentration terms said ratio is employed with the number "1" corresponding to a concentration of around 0.025 w/v.

24. A formulation according to any one of claims 1 to 23 which contains a low volatility component at between 0.5 and 3% (w/w).
25. A formulation according to claim 24 which contains between 1.0 and 1.6% (w/w) of the low volatility component.
- 5 26. A formulation according to claim 24 which contains 1.0% (w/w) of the low volatility component.
27. A formulation according to claim 24 which contains between 0.5 and 1.0% (w/w) of the volatility component.
28. A formulation according to claims 1 which comprises:
- 10 (i) 0.025-0.05% w/w salmeterol base;
(ii) 0.025-0.05% w/w fluticasone propionate;
(iii) 1,1,1,2-tetrafluoroethane as propellant;
(iv) 0.5-1% of a low volatility propellant selected from glycerol and polyethylene glycol; and
- 15 (v) 6-12% ethanol as solubilising agent.
29. A formulation according to claim 28 wherein the low volatility component is PEG200 or PEG400.
30. A formulation according to claim 28 wherein the low volatility component is glycerol.
- 20 31. A formulation according to any one of claims 1 to 30 further comprising a compound capable of preventing chemical degradation of salmeterol in the formulation.
32. A canister comprising a metering valve and containing a pharmaceutical aerosol formulation according to any one of claims 1 to 31.
- 25 33. A metered dose inhaler which comprises a canister as claimed in claim 32 fitted into a suitable channelling device.
34. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation according to any one of claims 1 to 31.
- 30 28. Use of a pharmaceutical aerosol formulation according to any one of claims 1 to 31 in the manufacture of a medicament for the treatment of respiratory disorders, eg. asthma or chronic obstructive pulmonary disease (COPD).

Figure 1





Figure 2



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04939

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 416 951 A (GLAXO GROUP LTD) 13 March 1991 (1991-03-13) examples 1-5	1-30, 32-35
Y	US 5 653 962 A (AKEHURST RACHEL ANN ET AL) 5 August 1997 (1997-08-05) examples 17-20,24 --- -/--	1-30, 32-35

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

9 March 2001

Date of mailing of the international search report

28.03.01

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Borst, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/04939

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 98 56349 A (BRAMBILLA GAETANO ;LEWIS DAVID (IT); VENTURA PAOLO (IT); GANDERTON) 17 December 1998 (1998-12-17) page 1, line 12 -page 1, line 18 page 5, line 7 -page 6, line 31 page 7, line 1 -page 7, line 4 page 8, line 1 -page 8, line 7 page 11, line 24 -page 11, line 28 page 12, line 6 -page 12, line 14 page 13, line 20 -page 13, line 23 page 14, line 6 -page 14, line 11 page 14, line 16 -page 14, line 22 claim 9</p>	<p>1-19, 21-30, 32-35</p>
Y	<p>WO 98 24420 A (GOODMAN MICHAEL ;BIOGLAN IRELAND R & D LTD (IE); MCCARTHY PAUL (IE) 11 June 1998 (1998-06-11) page 7, line 5 -page 8, line 5 page 8, line 12 -page 8, line 17</p>	<p>1,3,4, 11-23</p>
Y	<p>WO 94 13262 A (JAGER PAUL D ;KONTNY MARK J (US); NAGEL JURGEN H (DE)) 23 June 1994 (1994-06-23) page 4, paragraph 5 -page 6, paragraph 1 page 7, last paragraph -page 8, paragraph 1</p>	<p>1,3,4, 11-23</p>
Y	<p>US 5 919 827 A (BARBERICH TIMOTHY J ET AL) 6 July 1999 (1999-07-06) column 2, line 9 -column 2, line 31</p>	<p>19</p>
P,Y	<p>WO 00 30607 A (BRAMBILLA GAETANO ;LEWIS DAVID (IT); VENTURA PAOLO (IT); GANDERTON) 2 June 2000 (2000-06-02) page 8, line 23 -page 9, line 2 page 10, line 4 -page 10, line 28</p>	<p>1-19, 21-30, 32-35</p>
A	<p>US 6 004 537 A (CAVANAUGH KELLY A ET AL) 21 December 1999 (1999-12-21) column 2, line 3 -column 2, line 24</p>	<p>1-35</p>
A	<p>WO 99 65464 A (BOEHRINGER INGELHEIM PHARMA) 23 December 1999 (1999-12-23) page 3, line 25 -page 4, line 33</p>	<p>1-35</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/04939

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 34 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 31
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 31

Present claim 31 relates to a compound defined by reference to a desirable property, namely the prevention of chemical degradation of salmeterol.

The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claim which appear to be clear, supported and disclosed, namely for basic stabilisers such as sodium or potassium hydroxide, sodium carbonate and organic amines (present description: page 10, line 27-29).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04939

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0416951 A	13-03-1991	AT 99941 T	15-01-1994
		BE 1003053 A	05-11-1991
		CA 2024916 A	09-03-1991
		CH 680983 A	31-12-1992
		CY 1817 A	20-10-1995
		DE 69005951 D	24-02-1994
		DE 69005951 T	26-05-1994
		DK 416951 T	14-02-1994
		ES 2062392 T	16-12-1994
		FR 2651677 A	15-03-1991
		GB 2235627 A, B	13-03-1991
		HK 18695 A	17-02-1995
		HU 9500150 A	28-08-1995
		IE 903256 A	13-03-1991
		IL 95590 A	18-06-1996
		IT 1241996 B	02-02-1994
		JP 3042867 B	22-05-2000
		JP 3167120 A	19-07-1991
		LU 90392 A	28-06-1999
		LV 5735 A	20-06-1996
		NZ 235221 A	25-11-1992
		PH 27594 A	31-08-1993
		SG 166294 G	16-06-1995
		US 5270305 A	14-12-1993
		ZA 9007136 A	26-06-1991
		AU 640682 B	02-09-1993
		AU 6226290 A	26-04-1991
US 5653962 A	05-08-1997	AP 402 A	22-08-1995
		AT 163539 T	15-03-1998
		AU 663904 B	26-10-1995
		AU 3085092 A	19-07-1993
		BG 62119 B	31-03-1999
		BG 98803 A	28-02-1995
		BG 102689 A	26-02-1999
		CA 2125667 A	24-06-1993
		CZ 9401430 A	15-03-1995
		DE 69224656 D	09-04-1998
		DE 69224656 T	23-07-1998
		DK 616523 T	28-09-1998
		WO 9311743 A	24-06-1993
		EP 1066828 A	10-01-2001
		EP 0616523 A	28-09-1994
		EP 0756868 A	05-02-1997
		EP 0990437 A	05-04-2000
		ES 2113444 T	01-05-1998
		HU 67534 A	28-04-1995
		HU 9500331 A	28-09-1995
		IL 104068 A	30-10-1998
		JP 11310533 A	09-11-1999
		JP 3026840 B	27-03-2000
		JP 7502033 T	02-03-1995
		MX 9207205 A	01-11-1993
		NO 942185 A	10-06-1994
		NO 20001227 A	10-06-1994
		NZ 246044 A	26-01-1996
		OA 9926 A	15-09-1994
		RU 2129424 C	27-04-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04939

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5653962 A		SG 74042 A	18-07-2000
		SK 67494 A	08-03-1995
		US 5674471 A	07-10-1997
		US 5676929 A	14-10-1997
		US 5674472 A	07-10-1997
		US 5658549 A	19-08-1997
		US 5683676 A	04-11-1997
		ZA 9209617 A	22-03-1994
		AT 171865 T	15-10-1998
		AU 663905 B	26-10-1995
		AU 3085192 A	19-07-1993
		CA 2125666 A	24-06-1993
		DE 69227257 D	12-11-1998
		DE 69227257 T	25-03-1999
		DK 616524 T	21-06-1999
		WO 9311744 A	24-06-1993
		EP 0616524 A	28-09-1994
		ES 2123576 T	16-01-1999
WO 9856349 A	17-12-1998	GB 2326334 A	23-12-1998
		AU 8626298 A	30-12-1998
		BG 103221 A	30-09-1999
		BR 9805993 A	31-08-1999
		CN 1229355 T	22-09-1999
		CZ 9900462 A	14-07-1999
		EP 0920302 A	09-06-1999
		HR 980317 A	30-04-1999
		HU 0001339 A	28-09-2000
		IT MI971798 A	28-01-1999
		JP 2000516965 T	19-12-2000
		NO 990594 A	13-04-1999
		PL 331531 A	19-07-1999
		SK 17699 A	12-07-1999
		TR 9900288 T	21-09-1999
		ZA 9805136 A	07-01-1999
WO 9824420 A	11-06-1998	AU 726510 B	09-11-2000
		AU 5402898 A	29-06-1998
		EP 1011646 A	28-06-2000
		IE 970858 A	12-08-1998
		NO 992677 A	15-07-1999
		ZA 9710923 A	02-09-1998
WO 9413262 A	23-06-1994	AT 177941 T	15-04-1999
		AU 680227 B	24-07-1997
		AU 5740594 A	04-07-1994
		AU 6048694 A	04-07-1994
		BG 62382 B	29-10-1999
		BG 99760 A	29-02-1996
		BR 9307627 A	15-06-1999
		CZ 9501490 A	13-12-1995
		DE 69324161 D	29-04-1999
		DE 69324161 T	28-10-1999
		DK 673240 T	11-10-1999
		EP 673240 A	27-09-1995
		ES 2129117 T	01-06-1999
		FI 952842 A	09-06-1995
		GB 2288978 A, B	08-11-1995

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/04939

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9413262 A		GR 3030529 T	29-10-1999
		HK 1011620 A	20-04-2000
		HU 72985 A	28-06-1996
		JP 3009924 B	14-02-2000
		JP 8509459 T	08-10-1996
		LV 10911 A	20-12-1995
		LV 10911 B	20-04-1996
		NO 952269 A	08-06-1995
		NZ 259192 A	26-05-1997
		PL 309333 A	02-10-1995
		SG 52459 A	28-09-1998
		SK 76095 A	08-01-1997
		WO 9413263 A	23-06-1994
		US 6045778 A	04-04-2000
		US 5676930 A	14-10-1997
		US 5955058 A	21-09-1999
		CN 1095265 A, B	23-11-1994
		RU 2126248 C	20-02-1999
		TW 403657 B	01-09-2000
		ZA 9309195 A	08-06-1995
US 5919827 A	06-07-1999	NONE	
WO 0030607 A	02-06-2000	AU 1555300 A	13-06-2000
US 6004537 A	21-12-1999	AU 2194900 A	03-07-2000
		WO 0035441 A	22-06-2000
WO 9965464 A	23-12-1999	DE 19827178 A	27-04-2000
		DE 19842963 A	23-03-2000
		AU 4552199 A	05-01-2000
		NO 20006318 A	30-01-2001